Cargando…

Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections

The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalski, Regis P., Nayyar, Shannon V., Romanowski, Eric G., Jhanji, Vishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868068/
https://www.ncbi.nlm.nih.gov/pubmed/35203807
http://dx.doi.org/10.3390/antibiotics11020204
_version_ 1784656175508226048
author Kowalski, Regis P.
Nayyar, Shannon V.
Romanowski, Eric G.
Jhanji, Vishal
author_facet Kowalski, Regis P.
Nayyar, Shannon V.
Romanowski, Eric G.
Jhanji, Vishal
author_sort Kowalski, Regis P.
collection PubMed
description The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no anti-infective susceptibility standards to interpret treatment success, but the systemic standards can be used to guide ocular therapy if the concentration of anti-infective in the ocular tissue is assumed to be higher than the concentration in the blood serum. This Perspective describes: (1) eye infections, (2) diagnostics of eye infections, (3) anti-infective treatment of eye infections, (4) anti-infective resistance of ocular pathogens, and (5) alternative anti-infective delivery and therapy. The data, based on years of clinical and laboratory research, support the premise that ocular infections are less problematic if etiologic agents are laboratory-diagnosed and if prompt, potent, anti-infective therapy is applied. Anti-infective susceptibility should be monitored to assure continued therapeutic success and the possibility of new-found resistance. New delivery systems and therapies may be helpful to better treat future ocular infections.
format Online
Article
Text
id pubmed-8868068
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88680682022-02-25 Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections Kowalski, Regis P. Nayyar, Shannon V. Romanowski, Eric G. Jhanji, Vishal Antibiotics (Basel) Perspective The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no anti-infective susceptibility standards to interpret treatment success, but the systemic standards can be used to guide ocular therapy if the concentration of anti-infective in the ocular tissue is assumed to be higher than the concentration in the blood serum. This Perspective describes: (1) eye infections, (2) diagnostics of eye infections, (3) anti-infective treatment of eye infections, (4) anti-infective resistance of ocular pathogens, and (5) alternative anti-infective delivery and therapy. The data, based on years of clinical and laboratory research, support the premise that ocular infections are less problematic if etiologic agents are laboratory-diagnosed and if prompt, potent, anti-infective therapy is applied. Anti-infective susceptibility should be monitored to assure continued therapeutic success and the possibility of new-found resistance. New delivery systems and therapies may be helpful to better treat future ocular infections. MDPI 2022-02-06 /pmc/articles/PMC8868068/ /pubmed/35203807 http://dx.doi.org/10.3390/antibiotics11020204 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Kowalski, Regis P.
Nayyar, Shannon V.
Romanowski, Eric G.
Jhanji, Vishal
Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections
title Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections
title_full Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections
title_fullStr Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections
title_full_unstemmed Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections
title_short Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections
title_sort anti-infective treatment and resistance is rarely problematic with eye infections
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868068/
https://www.ncbi.nlm.nih.gov/pubmed/35203807
http://dx.doi.org/10.3390/antibiotics11020204
work_keys_str_mv AT kowalskiregisp antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections
AT nayyarshannonv antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections
AT romanowskiericg antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections
AT jhanjivishal antiinfectivetreatmentandresistanceisrarelyproblematicwitheyeinfections